Treatment With the Radiolabeled Somatostatin Analog [ <sup>177</sup> Lu-DOTA <sup>0</sup> ,Tyr <sup>3</sup> ]Octreotate: Toxicity, Efficacy, and Survival
Dik J. Kwekkeboom(Erasmus MC), Eric P. Krenning(Cyclotron (Netherlands)), Richard A. Feelders(Erasmus MC), Boen L.R. Kam(Erasmus MC), Maarten O. van Aken(Erasmus MC), Martijn van Essen(Erasmus MC), Casper H.J. van Eijck(Erasmus MC), P.P.M. Kooij(Erasmus MC), Wouter W. de Herder(Erasmus University Rotterdam)
Cited by 1,445
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Gastroenteropancreatic neuroendocrine tumours
|The Lancet Oncology|2008|1.8k
Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial
|Journal of Clinical Oncology|2020|1.1k
FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
|The Lancet Oncology|2016|914